REG - Oncimmune Hldgs PLC - Siemens Healthineers Collaboration

Oncimmune HoldingsAnnouncement

17/02/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230217:nRSQ2022Qa&default-theme=true

RNS Number : 2022Q  Oncimmune Holdings PLC  17 February 2023

 

17 February 2023

 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

Siemens Healthineers and Oncimmune partner to improve malignancy risk
assessment of indeterminate pulmonary nodules

 

Collaboration will access data from the ECLS trial, the large randomised study
into the utility of EarlyCDT Lung in asymptomatic screening

 

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics
group, announces a collaboration with Siemens Healthineers aimed at improving
malignancy risk assessment of Indeterminate Pulmonary Nodules ("IPNs").

Lung cancer has the highest mortality rate and one of the worst five-year
survival rates of all cancers(1). What makes lung cancer so deadly is that the
symptoms are non-specific and patients often only seek medical attention when
tumors have exceeded a critical size, or when cancer cells have attacked the
lymph nodes or have metastasized. The best chance of survival is to diagnose
lung cancer as early as possible. Early detection and the introduction of
screening programs have the potential to substantially improve lung cancer
healthcare and clinical outcomes.

The collaboration brings together Oncimmune's EarlyCDT Lung blood test with
Siemens Healthineers' AI-Rad Companion Chest CT (computerised tomography), an
AI-powered radiology assistant that supports radiologists by performing
automatic post-processing, quantifying and interpreting data. By combining
autoantibody biomarker data with imaging results, it is anticipated that
malignancy risk assessment of IPNs can be improved.

The collaboration will access data from the Early Detection of Cancer of the
Lung Scotland (ECLS) trial, the large randomised study into the utility of
EarlyCDT Lung in asymptomatic screening.

Dr Adam M Hill, CEO of Oncimmune said: "If lung cancer is detected early when
it doesn't yet cause symptoms, the chances for curative treatment to work are
good: the average five-year survival rate for the earliest stage of the
disease can be as high as 90%. Oncimmune's easy-to-use EarlyCDT Lung blood
test has proven utility in successfully triaging patients with cancerous
nodules into early intervention. It is our hope that combining this test with
Siemens Healthineers' AI-Rad Companion Chest CT will improve diagnostic
accuracy in those patients with more difficult to diagnose lung cancer."

Sebastian Schmidt, MD, Head of Medical Affairs, Innovation and Strategy at
Siemens Healthineers Computed Tomography said: "Lung cancer screening is
proven to work and reduce mortality of this devastating disease. We believe
that additionally, further improvement in outcomes and efficiency gains will
be possible by combining imaging with lab markers - our collaboration with
Oncimmune is an important first step in this direction."

For further information:

 

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

contact@oncimmune.co.uk (mailto:contact@oncimmune.co.uk)

 

Singer Capital Markets (Nominated Adviser and Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

+44 (0)20 7496 3000

 

 

 

 

 

 

About Oncimmune

 

ImmunoINSIGHTS Service Business

 

Oncimmune is a leading immunodiagnostics developer, primarily focused on the
growing fields of immuno-oncology, autoimmune disease and infectious diseases.
The ImmunoINSIGHTS service business leverages Oncimmune's technology platform
and methodologies across multiple diseases, to offer life-science
organizations actionable insights for therapies across the development and
product lifecycle. Our core immune-profiling technology is underpinned by our
library of over eight thousand immunogenic proteins, one of the largest of its
kind. This helps identify trial participants and patients into clinically
relevant subgroups, enabling development of targeted and more effective
treatments.

 

Oncimmune's ImmunoINSIGHTS service business is based at the Company's
discovery research centre in Dortmund, Germany. The business platform enables
life science organizations to optimize drug development and delivery, leading
to more effectively targeted and safer treatments for patients.

 

The ImmunoINSIGHTS development team is based in the US and Europe and
Oncimmune is seeking to replicate the Dortmund facility in the US in the
medium term.

 

EarlyCDT Product Business

 

Oncimmune's immunodiagnostic technology, EarlyCDT®, can detect and help
identify cancer on average four years earlier than standard clinical
diagnosis. Our lead diagnostic test, EarlyCDT® Lung, targets a vast market
estimated to grow to £3.8bn by 2024. With over 200,000 tests already
performed for patients worldwide and its use being supported by peer reviewed
data in over 12,000 patients, we are poised to become an integral component of
future lung cancer detection programs, globally.

 

Oncimmune's diagnostic products business is located at its laboratory facility
in Nottingham, UK.

 

For more information, visit www.oncimmune.com (http://www.oncimmune.com)

 

About our partner, Siemens Healthineers

 

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers
breakthroughs in healthcare. For everyone. Everywhere. As a leading medical
technology company headquartered in Erlangen, Germany, Siemens Healthineers
and its regional companies are continuously developing their product and
service portfolio, with AI-supported applications and digital offerings that
play an increasingly important role in the next generation of medical
technology. These new applications will enhance the company's foundation in
in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and
innovative cancer care. Siemens Healthineers also provides a range of services
and solutions to enhance healthcare providers' ability to provide
high-quality, efficient care. In fiscal 2022, which ended on September 30,
2022, Siemens Healthineers, which has approximately 69,500 employees
worldwide, generated revenue of around €21.7 billion and adjusted EBIT of
almost €3.7 billion. Further information is available at
www.siemens-healthineers.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSFUFMMEDSEFE